Methods: In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (27 in persons with 1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention
By adding medications to your weight loss plan, you can overcome frustrating plateaus and gain an invaluable boost in the fight against obesity and other issues like diabetes
Navigating healthcare can be challenging, but finding the right primary care physician shouldn't be
Additionally, Zepbound (tirzepatide for weight management) shares the same active compound as Mounjaro and thus appears to carry a similar risk profile for hair thinning
Our guide details efficacy, side effects, and patient experiences